Sanofi-Aventis CEO Plans Focus Switch From West To China
This article was originally published in PharmAsia News
France's Sanofi-Aventis told reporters it plans to take advantage of China's massive health-reform plan by expanding its Chinese business. To do so, Sanofi-Aventis is switching its emphasis away from reliance on blockbuster drugs in the developed world. The firm's CEO Christopher Viehbacher told reporters he will not be satisfied with just operating on the margins of China's healthcare system. Viehbacher said the company is looking for acquisitions, joint ventures or equity stakes with Chinese drug makers to give the company a large presence in basic drugs. (Click here for more - a subscription may be required
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.